Medicine and Dentistry
Therapeutic Procedure
100%
Metastatic Breast Cancer
100%
Antigestagen
100%
Hormone Therapy
28%
Tissues
14%
Disease
14%
Gene
14%
Combination Therapy
14%
Patient
14%
Estrogen Receptor
14%
Progesterone Receptor
14%
Inpatient
14%
Targeted Therapy
14%
Hormone Receptor
14%
Functional Imaging
14%
Cell Proliferation
14%
Prognosis
14%
Gamma Urogastrone
14%
Epidermal Growth Factor Receptor 2
14%
Phosphoinositide 3-Kinase
14%
Gene Mutation
14%
Estrogen Receptor Alpha
14%
Phosphoinositide 3-Kinase Inhibitor
14%
Mammalian Target of Rapamycin Inhibitor
14%
Cyclin-Dependent Kinase
14%
Cyclin-Dependent Kinase
14%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Breast Cancer
100%
Antigestagen
100%
Endocrine Therapy
40%
Diseases
20%
Clinical Trial
20%
Cell Proliferation
20%
Preclinical Study
20%
Progesterone Receptor
20%
Estrogen Receptor
20%
Mammalian Target of Rapamycin Inhibitor
20%
Hormone Receptor
20%
Clinical Study
20%
Cytotoxic Chemotherapy
20%
Prognosis
20%
Gamma Urogastrone
20%
Epidermal Growth Factor Receptor 2
20%
Phosphatidylinositol 3 Kinase
20%
Phosphatidylinositol 3 Kinase Inhibitor
20%
Cyclin Dependent Kinase
20%
Estrogen Receptor Alpha
20%